January 28, 2002 - Ventria Bioscience Featured on Dr.Greene.com

DrGreene.com, a web leader in pediatric information, recently featured Ventria Bioscience in a story on the benefits of human lactoferrin and human lysozyme.

The feature, titled "Lactoferrin and Lysozyme Supplements", addressed the importance of these two proteins in breast milk. In addition to outlining lactoferrin and lysozyme's anti-infective properties , the story also promoted the human version of these proteins over bovine lactoferrin and egg white lysozyme.

With Ventria's production breakthrough, human lactoferrin and human lysozyme have the potential to be provided as supplements to infants who are unable to breast-feed as well as young children whose immune systems are still developing. Referring to Ventria's ability to produce both proteins, Alan Greene, MD FAAP, closes by saying, "This could become a great gift to the children of the world."

"It is a great compliment to be featured on one of the world's most recognized pediatric sites," said Scott Deeter, Ventria President and CEO. "This story is yet another compliment to ExpressTec'sÔ ability to produce proteins and peptides in a safe, scalable and cost-efficient manner."

To read Dr. Greene's Pediatric Update entitled "Lactoferrin and Lysozyme Supplements" in full, please click on the link below.

www.drgreene.com/21_1407.html

Ventria Bioscience is a development-stage biotechnology company engaged in the production of recombinant proteins using its proprietary ExpressTec™ technology to commercialize products with applications in human and animal health. Some of the products currently under development by Ventria address a variety of human health issues, including Infectious Disease and Iron Deficiency Anemia.

A complete archive of press releases is available on the World Wide Web at www.ventriabio.com/

For more information, please contact:
(916) 921-6148 ext. 57 or
info@ventriabio.com

Statements in this announcement other than historical data and information constitute forward looking statements that involve risks and uncertainties that could cause actual results to differ materially from those stated or implied by such forward-looking statements. Potential risks and uncertainties may include, but are not limited to, recent changes in senior management, fluctuations in operating results, market conditions and changes in technology and increased competition.